Supportive Oncodermatology in Pediatric Patients - 31/03/22
Doi : 10.1016/j.det.2021.12.007
Danny W. Linggonegoro, BS a, b, Hannah Song, MD a, b, Jennifer T. Huang, MD a, b, ⁎ 
a Boston Children's Hospital, Dermatology Program, 300 Longwood Avenue, Fegan 6, Boston, MA 02115, USA
b Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA
∗Corresponding author. 300 Longwood Avenue, Fegan 6, Boston, MA 02115.300 Longwood Avenue, Fegan 6BostonMA02115
Résumé |
Cutaneous reactions to targeted therapies are varied and common. Pediatric dermatology literature is emerging on the specific types and prevalence of cutaneous reactions to targeted therapies that hone in on membrane-bound receptors, intracellular signaling targets, and antiangiogenesis agents, as well as targeted immunotherapies. Data regarding the timing, severity, and treatment algorithms are most plentiful for BRAF, MEK, and EGFR inhibitors.
Le texte complet de cet article est disponible en PDF.Keywords : Oncodermatology, Targeted therapy, Pediatric dermatology, Cutaneous reaction, Management
Plan
© 2021
Elsevier Inc. Tous droits réservés.
Vol 40 - N° 2
P. 203-214 - avril 2022 Retour au numéro
Article précédent
- Morbilliform Eruptions in the Hospitalized Child
- Jessica S. Haber, Sarah D. Cipriano, Vikash S. Oza
- Laser Surgery for Dermatologic Conditions in Pediatric Patients
- Deepti Gupta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?